Roche's $8 billion InterMune Buy Not a Sign of More Big Deals

19.09.2014 - The decision by Swiss drugmaker Roche in August to buy US biotech company InterMune for $8.3 billion was "exceptional" and not a sign of more ambitious plans for major acquisitions...